NASDAQ:UMRXUnum Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Unum Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.55 -0.09 (-3.41 %) (As of 08/11/2020 11:10 AM ET) Add Compare Share Today's Range$2.47Now: $2.55▼$2.6550-Day Range$0.43MA: $2.11▼$3.3252-Week Range$0.29Now: $2.55▼$3.72Volume16,471 shsAverage Volume962,505 shsMarket Capitalization$79.46 millionP/E RatioN/ADividend YieldN/ABeta4.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingUnum Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, Unum Therapeutics has a potential upside of 43.8% from its current price of $2.55.Amount of Analyst CoverageUnum Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesUnum Therapeutics has received 181 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUnum Therapeutics has received 168 “underperform” votes. (Add your “underperform” vote.)Community SentimentUnum Therapeutics has received 51.86% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote “Outperform” if you believe UMRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUnum Therapeutics does not currently pay a dividend.Dividend GrowthUnum Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 31.50% of the stock of Unum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.19% of the stock of Unum Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unum Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unum Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unum Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnum Therapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UMRX Previous Symbol CUSIPN/A CIK1622229 Webwww.unumrx.com Phone617-945-5576Debt Debt-to-Equity Ratio0.16 Current Ratio3.37 Quick Ratio3.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales3.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book2.45Profitability EPS (Most Recent Fiscal Year)($1.04) Net Income$-31,830,000.00 Net Margins-99.09% Return on Equity-83.39% Return on Assets-48.69%Miscellaneous Employees72 Outstanding Shares31,160,000Market Cap$79.46 million Next Earnings DateN/A OptionableNot Optionable $2.55 -0.09 (-3.41 %) (As of 08/11/2020 11:10 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive UMRX News and Ratings via Email Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions How has Unum Therapeutics' stock price been impacted by Coronavirus (COVID-19)? Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UMRX stock has increased by 582.5% and is now trading at $2.55. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Unum Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unum Therapeutics. How were Unum Therapeutics' earnings last quarter? Unum Therapeutics Inc (NASDAQ:UMRX) issued its earnings results on Monday, May, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.10. The company earned $7.03 million during the quarter, compared to analysts' expectations of $3 million. Unum Therapeutics had a negative net margin of 99.09% and a negative return on equity of 83.39%. View Unum Therapeutics' earnings history. What price target have analysts set for UMRX? 4 analysts have issued 12 month price objectives for Unum Therapeutics' shares. Their forecasts range from $3.00 to $4.00. On average, they expect Unum Therapeutics' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price. View analysts' price targets for Unum Therapeutics. What are Wall Street analysts saying about Unum Therapeutics stock? Here are some recent quotes from research analysts about Unum Therapeutics stock: 1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (5/30/2020) 2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019) Has Unum Therapeutics been receiving favorable news coverage? Media coverage about UMRX stock has been trending neutral on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Unum Therapeutics. Are investors shorting Unum Therapeutics? Unum Therapeutics saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,980,000 shares, an increase of 375.4% from the June 30th total of 416,500 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is presently 0.7 days. Approximately 10.1% of the shares of the company are short sold. View Unum Therapeutics' Short Interest. Who are some of Unum Therapeutics' key competitors? Some companies that are related to Unum Therapeutics include Calithera Biosciences (CALA), Aeglea Bio Therapeutics (AGLE), Tiziana Life Sciences (TLSA), Concert Pharmaceuticals (CNCE), Selecta Biosciences (SELB), Osmotica Pharmaceuticals (OSMT), Avadel Pharmaceuticals (AVDL), Trevena (TRVN), MEI Pharma (MEIP), Immunic (IMUX), Bicycle Therapeutics (BCYC), Menlo Therapeutics (MNLO), ProQR Therapeutics (PRQR), MediciNova (MNOV) and Spero Therapeutics (SPRO). View all competitors. What other stocks do shareholders of Unum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Pennsylvania R.E.I.T. (PEI), BioNano Genomics (BNGO), KushCo (KSHB) and AEterna Zentaris (AEZS). Who are Unum Therapeutics' key executives? Unum Therapeutics' management team includes the following people: Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory BoardMr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)Mr. Larry Weiner, VP of Technical Operations When did Unum Therapeutics IPO? (UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers. What is Unum Therapeutics' stock symbol? Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX." How do I buy shares of Unum Therapeutics? Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Unum Therapeutics' stock price today? One share of UMRX stock can currently be purchased for approximately $2.55. How big of a company is Unum Therapeutics? Unum Therapeutics has a market capitalization of $79.46 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe. What is Unum Therapeutics' official website? The official website for Unum Therapeutics is www.unumrx.com. How can I contact Unum Therapeutics? Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
